Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ensysce Biosciences (ENSC) Net Income towards Common Stockholders (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Net Income towards Common Stockholders for 6 consecutive years, with -$3.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income towards Common Stockholders fell 663.51% to -$3.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$11.0 million, a 38.42% decrease, with the full-year FY2024 number at -$8.0 million, up 24.83% from a year prior.
  • Net Income towards Common Stockholders was -$3.7 million for Q3 2025 at Ensysce Biosciences, down from -$1.7 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $661769.0 in Q3 2024 to a low of -$17.2 million in Q3 2021.
  • A 5-year average of -$4.3 million and a median of -$2.7 million in 2023 define the central range for Net Income towards Common Stockholders.
  • Peak YoY movement for Net Income towards Common Stockholders: tumbled 1192.86% in 2021, then skyrocketed 124.61% in 2024.
  • Ensysce Biosciences' Net Income towards Common Stockholders stood at -$10.8 million in 2021, then soared by 49.06% to -$5.5 million in 2022, then surged by 36.54% to -$3.5 million in 2023, then decreased by 1.72% to -$3.6 million in 2024, then decreased by 4.62% to -$3.7 million in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Net Income towards Common Stockholders are -$3.7 million (Q3 2025), -$1.7 million (Q2 2025), and -$1.9 million (Q1 2025).